Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs

A single dose of psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebo-controlled study

by Eric W. Dolan
May 18, 2021
in Psychedelic Drugs
(Photo via Wikimedia Commons)

(Photo via Wikimedia Commons)

[Subscribe to PsyPost on YouTube to stay up-to-date on the latest developments in psychology and neuroscience]

Share on FacebookShare on Twitter

Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache. Their new findings, published in Neurotherapeutics, provide preliminary evidence that the drug could provide long-lasting therapeutic benefits to migraine sufferers.

Anecdotal reports have circulated for years that psilocybin lessens migraine symptoms. But there has been little scientific evidence to back the claims. The newly published research is the first double-blind, placebo-controlled study to examine whether psilocybin affects migraine disease.

“As a headache medicine physician, I see the need for a better understanding of headache disorders, including migraine, and the need for more treatment options. I’ve also studied the neuropharmacology of psychedelics for a number of years and appreciate their ability to help us understand more about the workings of the human brain,” explained study author Emmanuelle A. D. Schindler (@eadschindler), an assistant professor of neurology at Yale School of Medicine.

“When I learned that patients with certain headache disorders reported lasting improvements after just a single or few doses of psilocybin or other psychedelics, it made me wonder whether these drugs couldn’t help us better understand the underlying pathology in headache disorders, as well as serve as a new form of treatment.”

In the study, seven women and three men who suffered from frequent migraines first consumed a placebo capsule. At least two weeks later, they consumed a capsule containing a low dose of psilocybin. Both the participants and the research staff were unaware of which capsule contained the placebo and which capsule contained psilocybin. Two weeks before their placebo dose, the participants started to maintain a daily diary of their headache symptoms. They maintained this diary until two weeks after the active dose of psilocybin.

Schindler and her colleagues found that psilocybin was associated with a greater reduction in the frequency of migraines compared to placebo in the two weeks after capsule ingestion. Psilocybin was also associated with reductions in both headache pain severity and migraine-related functional impairments.

“This study is very preliminary and does not serve as a guide for how to manage migraine with psilocybin, but it does offer some important information. In this study, the effects of psilocybin on migraine (the disorder, not a single attack) were investigated. Psilocybin had a lasting effect on migraines, similar to the effect of taking a daily preventive medication, but psilocybin was only given a single time in this study,” Schindler told PsyPost.

“There is no other oral treatment that can do this. Furthermore, the dose in this study was a low dose, only minimally psychedelic, and people did not have to have a strong (or any) psychedelic experience when they took the drug to have a reduction in their migraine burden over the next couple weeks. This suggests that the acute effects of the drug while it’s in your body are not related to the improvement in migraine in the following weeks.”

The findings are in line with another study, published in 2015 by Schindler and her colleagues, which found that psilocybin mushrooms were being used to prevent and treat another type of painful headache disorder known as cluster headache, and were rated as more effective than conventional treatments. “Importantly, the doses used in cluster headache are typically on the low end and patients frequently express a dislike of taking higher doses,” Schindler noted.

Despite the promising findings, Schindler said that “there is a lot more research that needs to be done.”

“Different doses need to be studied and the effects and safety of repeating drug administration also need to be investigated,” she explained. “Ultimately, we still need to identify the doses and regimens that are safe and effective in managing migraine over the long-term. Migraine is a disease that stays with patients for decades, so we have to consider whether and how psilocybin might have a role in such a condition.”

“Migraine is also one of over a hundred distinct disorders that involve head and face pain, so what is learned here does not necessarily apply to these other disorders,” Schindler added. “It’s important to remember that there is no silver bullet when it comes to headache management. There are so many factors that contribute to migraine, including the brain, body, immune system, genetics, and environment, and there is no single treatment that will address all of them.”

“Psilocybin and related compounds might simply be added to the toolbox of treatment options. What we learned from this study though, is that psilocybin seems to work in a new way compared to other treatments, which is more valuable than simply replicating an already existing form of treatment.”

There were no serious adverse side effects reported by the participants. However, that doesn’t mean that psychedelic substances are completely safe. The participants underwent extensive physical and mental health screenings prior to the study, and they consumed psilocybin in a controlled setting.

“Psilocybin and other psychedelics are very powerful substances and can have significant physical and psychological consequences. Under certain conditions they can be safe, but this is not a group of compounds to be taken lightly,” Schindler said.

“We’re still learning how these drugs work and what they do to your body and mind, particularly over the long term. Researchers in the field are obsessed with safety because we know the great potential for these drugs to serve as medicines and don’t want to see their reputation tainted by unsafe practices (personal or commercial). Psychedelics are just re-emerging from decades of misunderstanding, fear, and stigma, and it won’t take much for them to fall prey to those influences again.”

The study, “Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin,” was authored by Emmanuelle A. D. Schindler, R. Andrew Sewell, Christopher H. Gottschalk, Christina Luddy, L. Taylor Flynn, Hayley Lindsey, Brian P. Pittman, Nicholas V. Cozzi, and Deepak C. D’Souza.

ShareTweetSendScanShareSharePin23Send

STAY CONNECTED

TRENDING

People are less satisfied with their marriage when their partner is not interested in social interactions, study finds

Individuals with secure emotional attachment are more likely to forgive and to be forgiven, study finds

Facing stigmatization due to depression can lower pain tolerance and increase catastrophizing

Owners of sex dolls are less prone to sexual aggression, but also have lower sexual self-esteem

Anxiety knowledge is lower in those who seek information on social media more often, study finds

Women whose male partners use porn more often tend to be less satisfied with emotional and sexual aspects of their relationship

RECENT

Masks hinder our ability to recognize facial expressions of sadness and fear

New research suggests populism and conspiracy mentality are both rooted in a fundamental disposition of distrust

Facing stigmatization due to depression can lower pain tolerance and increase catastrophizing

Individuals with secure emotional attachment are more likely to forgive and to be forgiven, study finds

Memory reactivation during sleep may not always improve memory consolidation

Women whose male partners use porn more often tend to be less satisfied with emotional and sexual aspects of their relationship

New research finds when small talk becomes awkward, we are more likely to blame ourselves

Heightened anxiety makes people more prone to share claims on social media

Currently Playing

People with dark personality traits are better at finding novel ways to cause damage or harm others

People with dark personality traits are better at finding novel ways to cause damage or harm others

People with dark personality traits are better at finding novel ways to cause damage or harm others

Dark Triad
Exercising in nature produces psychological benefits and measurable changes in brain activity

Exercising in nature produces psychological benefits and measurable changes in brain activity

Cognitive Science
People with social anxiety tend to engage in restrictive “safety behaviors” that make them less likable, study finds

People with social anxiety tend to engage in restrictive “safety behaviors” that make them less likable, study finds

Anxiety
Study helps untangle the complicated relationship between psychopathy and emotional awareness

Study helps untangle the complicated relationship between psychopathy and emotional awareness

Psychopathy
People exposed to phubbing by their romantic partner are less satisfied with their romantic relationship

People exposed to phubbing by their romantic partner are less satisfied with their romantic relationship

Relationships and Sexual Health
Paranormal beliefs are associated with worse sleep, study finds

Paranormal beliefs are associated with worse sleep, study finds

Mental Health
  • Cognitive Science
  • COVID-19
  • Mental Health
  • Social Psychology
  • Drug Research
  • Conspiracy Theories
  • Meditation
  • Psychology of Religion
  • Aviation Psychology and Human Factors
  • Relationships and Sexual Health
  • Evolutionary Psychology
  • Neuroimaging
  • Psychedelic Drugs
  • Dark Triad
  • Political Psychology

About

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Contact us
  • Privacy policy

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used.